Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-LIFT: Dulaglutide on Liver Fat
NCT03590626Completed
- Sponsor
- Medanta
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of dulaglutide in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Medanta. Primary endpoint: Change in liver fat quantified by MRI-PDFF at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
dulaglutide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03590626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590626.